ARTICLE | Company News
Mucosis, J&J deal
October 15, 2012 7:00 AM UTC
Mucosis granted Crucell N.V. rights to use Mimopath technology to develop vaccines against infectious diseases. The technology is based on the Lactococcus lactis bacteria, which Mucosis formulates in...